Georgetown University
The goal of this clinical trial is to find out if Five-fraction CyberKnife stereotactic body radiation therapy (SBRT) with real-time Synchrony® motion tracking can treat ultra-central nonsmall cell lung cancer while reducing the amount of serious side effects from SBRT. Participants will * receive radiation treatment every other day over two weeks using a machine called the CyberKnife®, which uses a technology called Synchrony® motion management, which tracks your tumor in real time as it moves with your breathing. This allows the radiation beam to follow your tumor during treatment, helping to deliver the radiation more accurately to the tumor while reducing the dose to nearby healthy organs. * return for follow up visits after treatment at months 3, 6, 9, 12, 18, 24 and then every year for 5 years to be evaluated * complete questionnaires before and after treatment.
Inclusion Criteria: 1. Patients aged 18 or older. 2. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 3. Patients with confirmed tumor location using advanced imaging to ensure accurate classification of ultra-central NSCLC. 4. Ability to undergo bronchoscopy and Endobronchial ultrasound (EBUS) with adequate fiducial placement 5. Histologically or cytologically confirmed clinical stage T1-T2 N0 M0 NSCLC (AJCC 9th edition), with maximum tumor diameter ≤5 cm. 6. Absence of overt radiological or bronchoscopy assessed gross endobronchial invasion, invasion of…
50 Grays (Gy) delivered in 5 fractions, delivered using Cyberknife with Synchrony motion tracking, every other day over 2 weeks.
Arctuva estimate
Verify or correct the compensation shown for this listing.